Loading...
Venetoclax for the treatment of newly diagnosed acute myeloid leukemia in patients who are ineligible for intensive chemotherapy
Acute myeloid leukemia (AML) is an aggressive hematological malignancy with a globally poor outcome, especially in patients ineligible for intensive chemotherapy. Until recently, therapeutic options for these patients included low-dose cytarabine (LDAC) or the hypomethylating agents (HMA) azacitidin...
Saved in:
| Published in: | Ther Adv Hematol |
|---|---|
| Main Authors: | , |
| Format: | Artigo |
| Language: | Inglês |
| Published: |
SAGE Publications
2019
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6811760/ https://ncbi.nlm.nih.gov/pubmed/31692757 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2040620719882822 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|